August 2014 Work Group Recaps:


Work Group 1 Telecommunication

Balloons:
- Ballot WG010062 (DERF 001190 (Benefit Stage), DERF 001192 (COB verbiage), DERF 001196 (Hyphen usage)) is considered a Valid Ballot having received 60% of Consensus Group votes. The Work Group adjudicated the comment received which was voted as not persuasive. The ballot will proceed to the Board of Trustees for approval after the required appeal period.
- Ballot WG010063 (DERF 001195 (Post Adjudication Transition File)) is considered a Valid Ballot having received 60% of Consensus Group votes and 75% approval. There were no comments. The ballot will proceed to the Board of Trustees for approval after the required appeal period.

DERFs/ECLs Reviewed:
- DERF 001188 was pended to the WG1 Benefit Integration Task Group at the February and May Work Groups to continue work on the standard. The DERF was approved with modifications.
- DERF 001191/ECL 000156 was pended at May Work Group for more work by the WG1 Vaccine Services Task Group. The DERF was pended for more work.
- DERF 001209/Emergency ECL 000160 was recommended to be approved to MC.
- DERF 001210/ECL 000161 was recommended to be pended for more work by the WG1 Vaccine Services Task Group to MC.
- DERF 001211/Emergency ECL 000162 was recommended to be approved to MC.
- DERF 001212/ECL 000163 was recommended to be approved to MC. (MC pended the DERF to the WG1 Information Reporting Problems Task Group.)
- DERF 001213 was pended for more work by WG1 Telecommunication FAQ Task Group.
- DERF 001214/ECL 000164 was recommended to be pended for more work by WG1 Telecommunication FAQ Task Group to MC.

Updates:
- A HIPAA Standards, Operating Rules, and regulations (HPID/ICD/NPI/EFT/ERA) update was given.
- Use of Quantity Prescribed (46Ø-ET) in the Telecommunication Standard claim billing - Note this field would be required for Part D Schedule II Controlled Substance claims; however the use of this field is not limited to Part D claims only.
  - Telecommunication D.0 and all versions from that point have been updated (November 2012).
  - 03/2014 NCPDP received a response from HHS to the 03/2013 letter. The change will go through NPRM and Final Rule process.
    - We have asked that the industry have input on the implementation timeframe before the NPRM is published.
    - We have asked for timeframe of NPRM publication.
  - 06/2014 Update: OESS has responded that an NPRM including Quantity Prescribed and SCRIPT electronic prior authorization is going through the review process.
  - WG1 Telecommunication FAQ Task Group will begin discussing a recommendation timeline for OESS.
- NCPDP SNIP Committee met to provide a testimony letter to NCVHS.

Task Groups:
- The **Telecommunication FAQ Task Group** discussed questions submitted. They submitted DERF 001209 Emergency ECL 000160 (Prescription Origin Code). Based on a question, they recommended a new task group be formed (see Standardized Subrogation Task Group).
- The **Coordination of Benefits Task Group** discussed questions submitted. They discussed CMS Chapter 14 items and Patient Assistance Programs. Question 46 was approved for publication.
The **Financial Information Reporting Task Group** discussed adding Gender Code to “Daily Cumulative FIR Reject Report” (it was done), plans with missing emails for FIR reports and reported to CMS, and they brought forward FAQs which were approved for the FIR FAQ document.

The **Information Reporting Problems Task Group** is finalizing the new data within the NCPDP SPAP ADAP BIN PCN list worksheet. They are preparing a SPAP ADAP TrOOP Attestation document and process. They brought forward DERF 001212/ECL 000163.

The **Post Adjudication Task Group** did not meet.

The **Safe Use Processing – REMS Task Group** disbanded.

The **Definition of a Valid Prescriber Task Group** brought forward DERF 001211 Emergency ECL 000162 (Reject/Approved Code values for State License authority). They are discussing bringing forward a DERF to postpone the implementation of values approved in May for DERF 001193/Emergency ECL 000157 and 001194/Emergency ECL 000158. They are working through questions and have reached out to the DOJ for an understanding of the prescriber enrollment workflow. The task group is building a white paper of recommendations and gaps.

The **Supplemental Payer Reporting Task Group** - the SPAP ADAP reports are on hold until after Part D Plan performance reports are active so the Part D Plans see their performance before the SPAP ADAP reports start. They will be working on educational materials.

The **Eligibility Verification Enhancements Task Group** have put on hold a project plan for a HIPAA demonstration project request to implement the Last Known 4Rx Segment in the next round of HIPAA.

The **Compound Billing Solutions Task Group** discussed remaining questions.

The **Transaction ID Task Group** brought forward best practices for Reversals for Telecommunication D.0 which was approved. They will begin re-examining the use of a unique transaction identifier for all Telecommunication transactions.

The **Vaccine Services Task Group** is completing recommendations for the Version D Editorial for pharmacy benefit billing for products, services, and products and services. They reviewed pended DERF 001191/ECL 000156 and submitted DERF 001210 ECL 000161 (Basis of Cost/Reimbursement value).

The **Benefit Integration Task Group** had a subgroup that worked hard to review requirements for a standard for plans to share information on deductible, copay and Out of Pocket (OOP) to correctly maintain the maximum out of pockets as described in the ACA. They updated pended DERF 001188 which was approved for ballot as a new standard.

The **Standardized Subrogation Task Group** was formed to analyze the Medicaid Subrogation Standard and enhancements for subrogation use by commercial payers for one standard encompassing both uses.

New Business:

- The WG1 Scope and Goals were approved.
- There was discussion of the proposal to move to two ballot periods per year.

**Work Group 2 Product Identification**

**Ballots:**

- Ballot WG020004 for a new standard Product Identifiers Version 1.0 passed with comments that were categorized by the Work Group. The negative vote was changed to affirmative. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

**Task Groups:**

- The **Structure Product Labeling Activities Task Group** tracks the activities of the SPL, offers suggestions to improve access and usability of the FDA Structured Product Label and Electronic Drug Listings, and monitors the work of the Guiding Coalition for feedback to the work group. The Coalition has sent 18 letters to the FDA and is working on five additional letters of recommendation.
- The **Product Review and Billing Unit Exception Task Group** is reviewing the exceptions within the implementation guide and issues that result from changes to existing products or release of new products.
- Reviewed two new QUIC forms.
  - Due to the concerns regarding billing and reimbursement of Copaxone 20 mg, all compendia agreed that their files of September 25, 2014 will reflect the change to one milliliter per syringe. The task group verified with Teva the alcohol swabs have not been included in the Copaxone 20 mg for over two years.

- The **NCPDP Product Identification Standard Task Group** submitted a DERF which was balloted for approval of the *NCPDP Product Identifiers Standard Implementation Guide*. The ballot received comments which the task group will review and submit a DERF for the November WG meeting for changes to the standard.

- The **SPL REMS Requirements Task Group** is to gather the data needed to develop a template for pharmaceutical manufacturers to use in electronic submission of all the components for risk evaluation and mitigation strategies (REMS) drugs to a central repository (DailyMed) via FDA’s Structured Product Labeling system. The REMS-related data elements have undergone SPL balloting. The schema that contains these data elements may be found on HL7’s balloting website under the filename “PORP_MT059999UV.xsd”. Generally speaking the data elements are focused on identifying different points in the medication use process, and the REMS requirements that stakeholders must meet at those points. Further information is available at: [http://www.hl7.org/special/Committees/projman/searchableProjectIndex.cfm?action=edit&ProjectNumber=1114](http://www.hl7.org/special/Committees/projman/searchableProjectIndex.cfm?action=edit&ProjectNumber=1114). We are awaiting the September 2014 HL7 Ballot Cycle. This is a major milestone in achieving the goal of standardization and codification of REMS via SPL.

- The **Dates Associated with Pharmaceutical Products Task Group** is to investigate definition inconsistencies, involve government agencies to make them aware of the issues, and provide education on the importance via a white paper or other means.
  - The Government Dates (FDA & CMS) are to be handled separate from the remaining Dates.
    - CMS provided the definitions of their Exit dates
    - Dates definitions were included in the last download of the DDR
  - FDA defined entry dates and exit dates. It was determined in June that the new compounding legislation did not provide additional guidance on the definitions with regard to entry and exit dates.
    - These date definitions will be monitored and any changes reported.
  - NSDE file terminations date project was reviewed at this meeting to coordinate the efforts of this TG and the TG in WG9.

- The **Naming Standards for Drugs, Biologics and Biosimilars Task Group** met with FDA representatives on May 1, 2014. The group sent a thank you letter to the FDA. Key Points of the letter:
  - Restated the need to ensure adoption of widely recognized and accepted standardized naming and coding practices for a wide array of data attributes about medications, including nonproprietary naming conventions
  - Provided slide demonstrating how NCPDP tracks prescriptions with the use of grouped data elements
  - Noted risks of making drug compendia data base changes for non-proprietary names
  - Reiterated problem created in the ado-trastuzumab emtansine/ trastuzumab emtansine situation and anticipation of similar challenges
  - Offered our assistance

The task group will investigate the substitutability of biologics and how they should be published.

- The **Review of Appendix B Reference Code Qualifiers Task Group** is to review the definitions of existing product identifiers for accuracy and update as appropriate. The task group has created a spreadsheet for values and definitions within “Appendix B” and will schedule calls after the August WG meetings.

- The **Application of the Billing Unit Standard Clarification Task Group** continues to make progress in identifying the rationale used to determine the billing unit from past QUIC forms/products reviews and is capturing the rationale/reasons for those decisions.
• An update on the joint **WG11 and WG2 Drug Description Task Group** was provided. See WG11 meeting minutes.

• An update on the **MC NDC Depletion Task Group** was provided. See MC meeting minutes.

**New Business:**

• **QUIC Form Review:**
  1. #201408 New Product by Novartis = BU=ml per Section 5.2.2 of the BUS
  2. #201411 Vasuderm Stasis Kit NDC 68040-801-01 = BU=one EACH kit per Section 5.5.1 of the BUS

• The WG2 Scope and Goals were approved.

**Work Group 3 Standard Identifiers**

**Old Business:**

• WG45 Provider Enrollment Task Group Update – ASC X12’s 274 work group is developing the requirements document for the provider enrollment data element changes requested by NCPDP.

**Task Groups:**

• The **Pharmacy and/or Combination ID Card Task Group** provided a report on the WEDI Health ID Card Sub-Workgroup’s development of a Subscriber Smart Cards white paper. The task group presented a revised *Health Care Identification Card Fact Sheet* supporting the changes in version 4.2 of the *Pharmacy and/or Combination ID Card Implementation Guide*. WG3 approved the revisions. The Fact Sheet will be published. The task group reported on an inquiry from CMS related to guidance for the use of digital pharmacy ID cards. WG3 recommended the task group develop guidance.

• The **Pharmacy ID Card Operating Rules Task Group** was disbanded as there is no current business need to develop ID Card Operating Rules.

**New Business:**

• The WG3 Scope and Goals were approved.

**Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards**

**Old Business:**

• Pharmaceutical Manufacturer Outreach – Phillip Scott, NCPDP, gave a presentation developed for the purpose of educating pharmaceutical manufacturers about NCPDP and the value of participation. Phillip is available to give this presentation to manufacturers upon request.

**Task Groups:**

• The **Reference Guide Task Group** presented an overview of the purpose and work of the task group to date.

• The **Medical/Biologics Task Group** did not meet this quarter.

• The **CMS Task Group** reported on the presentation to the Southern Association of Medicaid Pharmacy Administrators and the follow-up work that will be necessary to request their participation in NCPDP.

• The **Rebate Standard Update Task Group** is working on challenges identified with the implementation of version 07.00 of the Rebate Standard. A sub-task group is developing a glossary of terms.
  o The **Specialty Pharmacy Data Exchange Sub-Task Group** is seeking participation from specialty pharmacy representatives.

• The **Regulatory Tracking/Pedigree Task Group** met to review *Guidance for Industry – Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification* draft published by the FDA. NCPDP did not comment on the document.

• The **Formulary Management Survey Task Group** did not meet this quarter.

**New Business:**

• The WG7 Scope and Goals were approved.

**Work Group 9 Government Programs**

DERF Reviewed:
DERF 001215/Emergency ECL 000165 was recommended to be denied to Maintenance and Control as the proposed reject code does not clarify what action should be taken by the pharmacy.

Task Groups:

- The **Prescription Monitoring Program (PMP) Task Group** presented updated information for states that have prescription monitoring programs. The updated tracking document will be published.

- The **340B Task Group** prepared and distributed a letter to the AIDS Drug Assistance Program Coordinators to raise awareness about the NCPDP 340B Information Exchange Reference Guide.

- The **Medicare Part B Claim Billing for Dual Eligibles Task Group** continues to address the lack of a consistent process across all state Medicaid plans to allow for the electronic processing of claims for Part B covered products that are secondary to the dual eligible recipient’s Medicare Advantage plan. Participation from Medicaid representatives is needed.

- The **Health Insurance Exchange/Marketplace Task Group** brought forward questions and recommended responses for review and approval by Work Group 9. The FAQ document will be updated and published.

- The **Medicaid Subrogation FAQ Task Group** did not meet as no new questions were received. It was noted that WG1 formed a Standardized Subrogation Task Group to analyze the Medicaid Subrogation Standard and enhancements needed for subrogation use by commercial payers to allow for one standard encompassing both uses.

- The **Medicare Part D FAQ Task Group** brought forward questions and recommended responses for review and approval by Work Group 9. The FAQ document will be updated and published.
  - The **Data Sharing for Overutilizers Sub Task Group** completed the white paper, NCPDP Recommendations for a Standardized Process to Share Medicare Part D Opioid Overutilization Data Between Sponsors and the Standardized Overutilization Data Sharing template and submitted to the Standardization Co-Chairs for approval.

- The **Supplemental Payer Part D Reconciliation Standardization Task Group** continued to identify data elements for the reconciliation report and will work on developing a guide for the reconciliation report.

- The **Hospice Task Group** reviewed and submitted comments on CMS-1609-P Medicare Program; FY 2015 Hospice Wage Index and Payment Rate Update; Hospice Quality Reporting Requirements and Process and Appeals for Part D Payment for Drugs for Beneficiaries Enrolled in Hospice. The task group is reviewing the final guidance issued July 18, 2014, “Part D Payment for Drugs for Beneficiaries Enrolled in Medicare Hospice.”

New Business:

- WG9 reviewed Project 000038 and formed a new task group, Standardized Fraud, Waste and Abuse Training Attestation, to standardize the CMS required Fraud, Waste and Abuse attestation process.

- WG9 received an update on Government Programs and Industry Changes.

- The WG9 Scope and Goals were approved.

Work Group 10 Professional Pharmacy Services.

Task Group Reports:

- The **MTM Communications Task Group** continues to develop new functionality in the Specialty and HL7 CDA standards to support professional pharmacy.

- The **Acetaminophen Best Practices Task Group** is continuing efforts to develop a paper that enumerates best practice guidelines, acetaminophen awareness, tools and technology solutions in a hospital model.

- The **mL White Paper Task Group** has completed the white paper, and was disbanded. The white paper recommendations continue to be the focus of industry interest.

- The **Prescribable Medication Information at Point of Care Task Group** was disbanded with plans to reassess the scope and goals of the work and present a focused supportable plan for the
work and product at the November Work Group meeting. If approved a new task group will be formed.

New Business:
- The WG10 Scope and Goals were approved.
- The Work Group had a guest presentation by Tricia Lee Wilkins, Pharm D, PhD from the Office of the National Coordinator for Health IT on “Safety (User-Centered) Enhanced Design”. The presentation focused on achieving usability of IT systems from the perspective of the end user within the user’s established workflow.

**Work Group 11 ePrescribing & Related Transactions**

**Ballots:**
- Ballot WG110060 for SCRIPT (DERF 001176 (Written/Effective Date), 001178-001181, 001184-85 (Diabetes), 001202 (OBS), 001203 (Phone), 001204 (Former Name), 001208 (RelatesTo)) is considered a Valid Ballot having received 60% of Consensus Group votes and 75% approval. There were no comments. The ballot will proceed to the Board of Trustees for approval after the required appeal period.
- Ballot WG110061 for F&B (DERF 001174 (Harmonize Drug Types), 001175 (Alternate/Step), 001206 (Copay, etc.)) is considered a Valid Ballot having received 60% of Consensus Group votes and 75% approval. There were no comments. The ballot will proceed to the Board of Trustees for approval after the required appeal period.

**DERFs/ECLs Reviewed:**
- DERF 001200 was pended at May Work Group for more review by the XML Task Group. The DERF was approved with modifications.
- DERF 001201 was pended at May Work Group for more discussion. It was discussed as part of the MC Real-Time Benefit Check Analysis Task Group.
- DERF 001207 was pended at May Work Group for more discussion by the Formulary and Benefit Task Group. The DERF was withdrawn by the submitter.
- DERF 001216 was withdrawn by the submitter.
- DERF 001217 was approved.
- DERF 001218 was approved with modifications.
- DERF 001219 was approved with modifications.
- DERF 001220 was pended for more work by the Prior Authorization Workflow to Transactions Task Group.
- DERF 001221 was pended for more work by the ePrescribing Best Practices Task Group.
- DERF 001222 was pended for more work by the new Medication History Task Group.

Old Business:
- An industry update was provided on NCVHS Subcommittee on Standards, CMS (eprescribing), and DEA eprescribing for controlled substances and implementation activities.

**Task Groups:**
- The **Formulary and Benefit Task Group** worked on pended DERF 001175. They brought forward DERF 001219 (Min/Max Copay). They requested the approval of a Formulary and Benefit Implementation Recommendations document.
- **XML Task Group** reviewed submitted DERFs and brought forward recommendations.
- **NCPDP/HL7 Pharmacist Functional Profile Task Group** did not meet this quarter.
- **WG11 Electronic Prescribing Best Practices Task Group** provided recommendations for the SCRIPT Implementation Recommendations document on the use of Quantity Qualifier recommendations and RefillResponse with Drug Name Different. They reviewed pended DERF 001200 (Allergy Segment) and brought forward DERF 001217 (NewRxRequest fields) and DERF 001221 (Additional Quantity).
- An update was given from the **WG14 LTPAC ePrescribing Task Group**. The group focused its efforts on capturing industry conventions for use of SCRIPT 10.6 in long-term and post-acute care settings, for use by facility vendors and pharmacies that are migrating HL7 interfaces to the SCRIPT Standard (to meet the Medicare ePrescribing standards).
• **REMS and ePrescribing Task Group** has refined their use cases between prescriber, pharmacy, REMS Administrator, and switch/intermediary for safe use programs. They have identified needed data elements. They are working through flows from basic REMS to complex REMS exchanges. They will work through the actual transactions and then updates to an implementation guide. They have provided trigger/data element analysis information to the WG2 SPL Task Group.

• The **Electronic Prior Authorization Workflow to Transactions Task Group** met to discuss next steps from input received during discussion of DERF 001169 that received three pends. They are working through flows of alternative methods of ePA exchanges. They discussed DERF 001220 (PA Limited Approval). **The task group will begin discussing a recommendation timeline for OESS.**

• The **WG11/2 Joint Drug Description Task Group** continued work on a project with NLM for creating processes for supporting RxNorm eprescribing names. The first file version was released by NLM in July. They are working through programmable rules for injectable names. They brought forward a question on representative NDC which was modified and will be updated in documentation.

• The **Meaningful Use and NIST Test Methods for ePrescribing Task Group** did not meet.

• **Implementation of Structured Sig Task Group** is building guidance on implementation and Q&A from implementers. They have collected top used sigs, created examples of those sigs, and are building guidance.

• **Specialty Requirements for ePrescribing Task Group** requested approval for recommendations for the **SCRIPT Implementation Recommendations** document. They will work on the next low hanging fruit data elements for specialty eprescribing needs.

• A new **Medication History Task Group** was formed to analyze and clarify DERF 001222.

**New Business:**

• The WG11 Scope and Goals were approved.

• The attendees discussed a timely, predictable, repeatable regulatory and implementation timeline process to name the next version of SCRIPT for electronic prescribing. They discussed the changes to the SCRIPT Standard since version 10.6. See the minutes for more in depth information.

• There was discussion of the proposal to move to two ballot periods per year.

**WG14 Long Term and Post Acute Care (LTPAC)**

**Old Business:**

• Industry/Regulatory updates were provided which included HIPAA and NCVHS.

**Task Group Reports:**

• The **ePrescribing Task Group** provided guidance for the use of the NCPDP SCRIPT Standard v10.6 for long term and post-acute care setting that was approved by both WG11 and WG14 for inclusion into the **SCRIPT Implementation Recommendations** document. The Task Group will continue working on additional guidance as well as working changes needed for LTPAC for the next version of SCRIPT.

• The **LTPAC Current Billing Issues Task Group** did not meet during the last quarter. Everyone is encouraged to participate in the in the WG11 ePA to Workflow Task Group and MC Real Time Benefit Task Group as these two topics are important to the LTPAC setting.

• Received updates from the **WG1 Eligibility Verification Enhancements Task Group**, the **WG9 Medicare Part D FAQ Task Group** and the **WG9 Hospice Task Group**.

**New Business:**

• Received information about the American Society of Consultant Pharmacist Annual Meeting and Exhibition to be held November 5-7, 2014 in Orlando, FL.

• The WG14 Scope and Goals were approved.

• Discussed the next version of SCRIPT for implementation through regulation. To be further discussed with WG11.

• Discussed the change to the ballot process proposal.
**Work Group 16 Property & Casualty/Workers Compensation**

**Old Business:**
- An IAIABC update was provided.

**Task Group Reports:**
- The **Legislative/Regulatory Monitoring and Education Task Group** provided an update on state regulatory and legislative initiatives affecting Workers’ Compensation programs.
- The **Billing and State Reporting Task Group** provided an update regarding states moving to adopt regulations for e-billing, standard paper billing and EDI reporting. The task group has completed development of content for a WEDI white paper to explain the handling of the special requirements for workers compensation in pharmacy billing.

**New Business:**
- The WG16 Scope and Goals were approved.

---

**Work Group 45 External Standards Assessment, Harmonization and Implementation Guidance**

**Old Business:**
- Industry updates were provided for WEDI, ASC X12, and CAQH CORE.

**Task Groups:**
- The **Document Revision Task Group** presented requirements for modifications to the CARC mapping document. Five new codes will be requested for Other Amount Paid: Delivery Cost, Shipping Cost, Postage, Administrative Cost and Compound Prep Cost.
- The **834/835 FAQ Task Group** received no new questions, therefore did not meet.
- A **DSMO Task Group** received no new DSMO Change Requests.
- The **Provider Enrollment Task Group** did not meet. The previously submitted ASC X12 Change Request is actively being reviewed at this time. The task group will remain open to monitor the progress of the request and the possible announcement by CMS provider enrollment regulation.
- The **Central Pay Task Group** completed its work prior to the February work group meeting. The content was reformatted from the spreadsheet to a standard guidance document and the **NCPDP Central Pay Reporting on the ASC X12/005010X221A1 Health Care Claim Payment Advice (835)**, is moving through the Inter SDO approval process. Once approved the task group will disband.

**New Business:**
- The WG45 Scope and Goals were approved.

---

**MC Maintenance and Control**

**Ballots:**
- Ballot WG020004 (DERF 001198) for a new standard Product Identifiers Version 1.0 is considered a Valid Ballot having received the required minimum 60% of Consensus Group votes. See Letter Ballot Comment spreadsheet for the ballot results. The comments were categorized as persuasive and editorial with the corrections made and not persuasive. The negative vote was changed to affirmative. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.
- Ballot WG010062 (DERF 001190 (Benefit Stage), DERF 001192 (COB verbiage), DERF 001196 (Hyphen usage)) is considered a Valid Ballot having received 60% of Consensus Group votes. The Work Group adjudicated the comment received which was voted as not persuasive. The ballot will proceed to the Board of Trustees for approval after the required appeal period.
- Ballot WG010063 (DERF 001195 (Post Adjudication Transition File)) is considered a Valid Ballot having received 60% of Consensus Group votes and 75% approval. There were no comments. The ballot will proceed to the Board of Trustees for approval after the required appeal period.
- Ballot WG110060 for SCRIPT (DERF 001176 (Written/Effective Date), 001178-001181, 001184-85 (Diabetes), 001202 (OBS), 001203 (Phone), 001204 (Former Name), 001208 (RelatesTo)) is considered a Valid Ballot having received 60% of Consensus Group votes and 75% approval.
There were no comments. The ballot will proceed to the Board of Trustees for approval after the required appeal period.

- Ballot WG110061 for F&B (DERF 001174 (Harmonize Drug Types), 001175 (Alternate/Step), 001206 (Copay, etc.)) is considered a Valid Ballot having received 60% of Consensus Group votes and 75% approval. There were no comments. The ballot will proceed to the Board of Trustees for approval after the required appeal period.

DERFs/ECLs

20 new and pended DERFs/ECLs were reviewed (see WG1, WG9 and WG11 above). The DERFs approved at this meeting will result in:

- Three ballots for the August 2014 ballot period
  - WG010064 for Benefit Integration Standard Implementation Guide v10
  - WG110062 for SCRIPT and Specialized
  - WG110063 for Formulary and Benefit v43

Old Business:

- Updates given:
  - HIPAA
  - NCPDP Legislative/Regulatory Activities
  - New Project Development Form #000038 requesting the creation of a new task group to look at creating standard attestation form was approved resulting in new task group under WG9 Government Programs.

Task Groups:

- The Education/Legislation and Regulations Task Group did not meet.
- The Ordering of Diabetic Supplies Standard Task Group has completed their work and disbanded.
- The NDC Depletion Task Group began working on a white paper of best practices for use of product identifiers and how to address changes after the approval of the Product Identification Standard.
- The PDMP White Paper Task Group reported on the activities of the S&I Framework PDMP group. Currently they are working with the S&I Framework in updating their Implementation Guide based on the use of the SCRIPT Medication History Request and Response transaction. To participate in the PDMP & Health IT Integration Initiative complete the “Join this Initiative” form on the PDMP & Health IT Integration Join the Initiative wiki page.
- The Unique Device Identifier (UDI) Task Group reviewed fields in the NCPDP Standards where the UDI could possibly be reported.
  - Worked with the owners of the standards to determine necessary Implementation Guide Changes.
  - Submitted a DERF for the recommended changes, which was pended back to the task group for additional work.
- The Real Time Benefit Check Task Group reported they have been creating use cases in preparation for a survey to determine what their initial focus should be.

New Business:

- The attendees received daily Work Group recaps.
- The MC Scope and Goals were approved.
- A new Sig in Transactions Task Group was formed to determine the value of including the Sig in NCPDP transactions. If value is found they will recommend which standards should incorporate and how the Sig should be implemented.
- Received an overview of the NCPDP Collaborative Workspace Calendar.
- Reviewed a proposed change to the ballot process and made a recommendation to the Standardization Co-Chairs to approve the proposal with the ballot cycles corresponding to the February and August Work Groups.